Ocular Therapeutix, Inc. filings document the formal disclosure record for a Nasdaq-listed biopharmaceutical issuer developing and commercializing ophthalmic therapies. Form 8-K reports furnish operating and financial results, Regulation FD materials and clinical-trial disclosures tied to AXPAXLI in wet age-related macular degeneration, along with material-event reporting on governance matters, executive officer arrangements, material agreements and capital-structure disclosures.
Proxy materials cover shareholder voting matters, executive compensation and equity-award disclosures, including information presented under pay-versus-performance reporting. The filings also identify Ocular Therapeutix common stock, par value $0.0001 per share, as registered on The Nasdaq Global Market under the symbol OCUL.
OCULAR THERAPEUTIX, INC (OCUL) insider Sanjay Nayak, Chief Strategy Officer, reported a sale of 1,897 shares of Common Stock on 2026-08-24 at a weighted average price of $10.78 per share. The shares were sold pursuant to a durable automatic Rule 10b5-1 sell-to-cover instruction to satisfy tax withholding on RSUs vesting on 2026-08-22 and are described as non-discretionary. Following this transaction, Nayak directly holds 326,898 shares of OCUL common stock.
OCULAR THERAPEUTIX, INC (OCUL) reported that Chief Scientific Officer Jeffrey S. Heier sold 3,296 shares of common stock on August 24, 2026 at a weighted average price of $10.78 per share. The sale was made under a durable automatic sale instruction adopted on April 9, 2024 to effect a sell-to-cover election for tax withholding on restricted stock units vesting on August 22, 2026, and is described as non-discretionary. Following this transaction, Heier beneficially owns 318,326 shares, which include 1,272 shares acquired under the company’s Amended and Restated 2014 Employee Stock Purchase Plan on June 30, 2026.
OCULAR THERAPEUTIX, INC (OCUL) reported insider activity by Executive Chairman, President and CEO Pravin Dugel. On August 24, 2026, he sold 21,649 shares of common stock at a weighted average price of $10.77 per share in open-market transactions, pursuant to a durable automatic Rule 10b5-1 sale instruction adopted on February 21, 2024, to satisfy tax withholding obligations related to restricted stock units vesting on August 22, 2026. Following this sale, he directly held 2,525,429 common shares. On August 25, 2026, his spouse transferred 50,092 shares as a bona fide gift to the Pravin Dugel 2024 Irrevocable Trust for no consideration; Dugel is trustee and lifetime sole beneficiary, and remains the beneficial owner. As a result, indirect holdings shifted from 50,092 shares held by spouse to 744,903 shares held through the trust.
OCULAR THERAPEUTIX, INC. (symbol OCUL) received a notice under Rule 144 that officer Sanjay Nayak intends to sell up to 1,897 shares of common stock. The shares relate to restricted stock vesting under a registered plan, with sales to be effected through Morgan Stanley Smith Barney LLC Executive Financial Services. The filing also reports that during the prior three months, Sanjay Nayak sold 1,858 shares of OCUL common stock on 05/26/2026 for $15,236.53.
OCULAR THERAPEUTIX, INC. (OCUL) received a Notice of Proposed Sale of Securities on Form 144 filed for officer Pravin Dugel. The notice covers a proposed sale of 21,649 shares of common stock, relating to restricted stock scheduled to vest on August 22, 2026, to be sold through Morgan Stanley Smith Barney LLC. The filing also reports that Dugel sold 21,156 shares of common stock during the prior three months for aggregate proceeds of $173,513.05.
OCULAR THERAPEUTIX, INC. (OCUL) is the issuer of common stock that Jeffrey S. Heier plans to sell under Rule 144. A notice covers a proposed sale of 3,296 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $35,532.20, tied to restricted stock vesting under a registered plan. The filing also reports that Heier sold 3,018 common shares over the prior three months for $24,745.19.
OCULAR THERAPEUTIX, INC. (OCUL) received a Rule 144 notice from officer Peter Kazuo Kaiser covering a planned sale of company common stock. The notice lists 3,035 shares of common stock to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with an indicated aggregate value of $32,701.82. The shares relate to restricted stock vesting under a registered plan, with vesting and proposed sale timing noted in August 2026. The filing also reports that over the prior three months, Peter Kazuo Kaiser sold 2,967 shares of OCUL common stock for total proceeds of $24,333.55.
Ocular Therapeutix reported second quarter 2026 total net revenue of $13.5 million, essentially unchanged from a year earlier, and a net loss of $(78.8) million, or $(0.35) per share. Cash and cash equivalents were $598.6 million as of June 30, 2026, which the company believes will fund planned operating expenses, debt service and capital spending into 2028 based on current plans.
The company is prioritizing AXPAXLI (OTX-TKI) for wet age-related macular degeneration. After a positive FDA Type C meeting, it plans to submit a wet AMD NDA in Q4 2026 via the Section 505(b)(2) pathway, following a pre-NDA meeting in Q3 2026. The NDA is expected to rely on Phase 3 SOL-1 Week 52 efficacy and safety data, interim SOL-R safety data, and confirmatory evidence. In SOL-1, 74.1% of AXPAXLI-treated subjects maintained vision at Week 36 and 65.9% at Week 52, both statistically superior to aflibercept. A post-hoc analysis estimates up to a 72% reduction in intravitreal injection burden over 60 weeks versus a projected on-label aflibercept regimen.
BlackRock, Inc. reports its beneficial ownership of common stock of Ocular Therapeutix, Inc. on an amended Schedule 13G. As of June 30, 2026, BlackRock beneficially owned 15,227,768 shares of common stock, representing 7.0% of the outstanding class.
BlackRock has sole voting power over 14,910,631 shares and sole dispositive power over all 15,227,768 shares, with no shared voting or dispositive power. Various underlying clients have economic interests in these shares, but no single client holds more than five percent of Ocular Therapeutix’s outstanding common stock.